Episode Details
Back to Episodes
Pharmaceutical Executive Daily: FDA Approves Hepcludex
Published 1 month, 2 weeks ago
Description
In today’s Pharmaceutical Executive Daily, Eli Lilly announces three acquisitions totaling roughly $3 billion, the FDA approves Hepcludex as the first treatment for chronic hepatitis delta virus infection in the United States, and biotech finance leaders reflect on the lessons learned from navigating two decades of volatile markets.